SynthesisExpert review of anti-infective therapy2017
Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials.
Synthesis in Expert review of anti-infective therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials.Advances in therapy · 2020Pooled it
- Can we distinguish respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature review.Reviews in medical virology · 2018Pooled it
- Article
- In-Hospital Complications of Influenza A and B Among Hospitalized Australian Children in the Post-COVID Era.The clinical respiratory journal · 2026Article
- Respiratory bacterial and viral pathogen spectrum among influenza-positive and influenza-negative patients.BMC infectious diseases · 2025Article
- Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study.Influenza and other respiratory viruses · 2025Article
- Article
- Viral co-detection of influenza virus and other respiratory viruses in hospitalized Brazilian patients during the first three years of the coronavirus disease (COVID)-19 pandemic: an epidemiological profile.Frontiers in microbiology · 2024Article
- The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review.Current rheumatology reports · 2023Review
- Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Airborne transmission of biological agents within the indoor built environment: a multidisciplinary review.Air quality, atmosphere, & health · 2023Review
- Article
- Article
- A retrospective analysis of respiratory virus transmission before and during the COVID-19 pandemic in Pune the western region of India.Frontiers in public health · 2022Article
- Lower respiratory tract infection in the community: associations between viral aetiology and illness course.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Article
- Role of Respiratory Syncytial Virus in Pediatric Pneumonia.Microorganisms · 2020Review
- Update on current views and advances on RSV infection (Review).International journal of molecular medicine · 2020Article
- Advancing challenges in Paediatric Virology: An interview with Professor Barbara A. Rath, Co-founder and Chair of the Vienna Vaccine Safety Initiative.Experimental and therapeutic medicine · 2019Article
- Partnering for enhanced digital surveillance of influenza-like disease and the effect of antivirals and vaccines (PEDSIDEA).Influenza and other respiratory viruses · 2019Article
- The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfluenza-Like Illness is a leading cause of hospitalization in children. Disease burden due to influenza and other respiratory viral infections is reported on a population level, but clinical scores measuring individual changes in disease severity are urgently needed. Areas covered: We present a composite clinical score allowing individual patient data analyses of disease severity based on systematic literature review and WHO-criteria for uncomplicated and complicated disease. The 22-item ViVI Disease Severity Score showed a normal distribution in a pediatric cohort of 6073 children aged 0-18 years (mean age 3.13; S.D. 3.89; range: 0 to 18.79). Expert commentary: The ViVI Score was correlated with risk of antibiotic use as well as need for hospitalization and intensive care. The ViVI Score was used to track children with influenza, respiratory syncytial virus, human metapneumovirus, human rhinovirus, and adenovirus infections and is fully compliant with regulatory data standards. The ViVI Disease Severity Score mobile application allows physicians to measure disease severity at the point-of care thereby taking clinical trials to the next level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.